The we deliver to canada viagra European Medicines Agency (EMA), in collaboration with other organisations involved in assessing the benefits and risks of vaccines, has launched a project to deliver a blueprint for a pan-European framework for monitoring the benefits and risks of vaccines throughout their lifecycle, and for communicating these benefits and risks.  This framework will further facilitate health professionals, regulatory agencies, public-health institutions what is viagra soft tabs and the general public to make prompt, better-informed decisions regarding vaccination strategies.


The five-year project, called accelerated development of vaccine benefit-risk collaboration in EuropeExternal link icon (ADVANCE), is supported by the Innovative Medicines Initiative (IMI) and brings together the EMA and the European Centre for Disease Prevention and ControlExternal link icon (ECDC), as well as pharmaceutical companies that manufacture vaccines, national public-health and regulatory bodies, academic experts and small and medium-sized enterprises. ADVANCE is coordinated by the Erasmus Medical CenterExternal link icon in the Netherlands and the Children’s Hospital BaselExternal link icon, University of Basel, Switzerland.


Vaccines undergo rigorous safety testing before regulatory approval. However, as shown in the context of the A/H1N1 pandemic, efforts to monitor vaccination coverage and the benefits and risks of vaccines after approval are fragmented. The goal of ADVANCE is to review, develop and test methods, data sources and procedures that will guide the development of a European framework that can ultimately deliver data for the assessment of the benefits and risks of vaccines.


The role of the EMA in ADVANCE will be to develop and test guidance for the conduct and reporting of studies in this area. This best-practice guidance will include methodological standards, governance rules, a code of conduct and a communication strategy.


Posted on the EMA website on 26 November 2013